Iconovo terminates liquidity guarantee agreement
The liquidity guarantee with DNB Carnegie ends after June 30, 2026, and the company considers the liquidity satisfactory.
See the latest news and media coverage for Iconovo. We track all announcements, press releases, and industry mentions in real time, all in one place.
Inhalation medicine development company
iconovo.seLast updated
In short: Iconovo appointed Anders Månsson as permanent CEO, secured significant funding through share issues, and partnered with Lonza.
The liquidity guarantee with DNB Carnegie ends after June 30, 2026, and the company considers the liquidity satisfactory.
The agreement focuses on spray-dried formulation for inhalable biologics.
Net sales increased to 675 kSEK and the loss decreased to -8 093 kSEK compared to the same period last year.
Proposals for decision on new board member, issue authorization and warrant program are processed.
SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2026In January 2026, it was announced that the European Patent Office (EPO) had declared its intention to...
Iconovo AB (publ) has today appointed Anders Månsson as permanent CEO of Iconovo AB after approximately 6 months of service as interim CEO. Anders Månsson...
Iconovo reported its Q4 2025 earnings with a revenue of 500,000, surpassing the forecast of 400,000 by 25%. However, the company posted a negative EPS...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN...
Track Iconovo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Iconovo and other trending companies.